RadioMedix, Inc. is a clinical-stage biotechnology company based in Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company commercializes radiopharmaceuticals for PET imaging and targeted alpha and beta-emitter therapy.

RadioMedix, Inc.

SmartMedix

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radio-pharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radio-pharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radio-labeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.

RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.

Portland Investment Counsel

Radiomedix, Inc. 

We are excited to share that the Inc Magazine's upcoming issue will feature the life story of Dr. Ebrahim (Abe) S. Delpassand, the CEO of Radio Medix. In the interview, he will discuss his groundbreaking work in radiopharmaceuticals and the future of cancer care. We are excited to offer readers a glimpse into Dr. Delpassand’ s visionary approach.

#RadioMedix #DrEbrahimDelpassand #PET #Cancer #NETcancerday
#Nuclearmedicine #PSMA #PsmaPET

https://lnkd.in/gDr2YFrJ

DelveInsight’s latest Neuroendocrine Tumor pipeline report depicts a robust space, with 55+ active players working to develop 60+ pipeline therapies for Neuroendocrine Tumors treatment. 

Major pharma and biotech giants such as Jiangsu Hengrui Pharmaceuticals Co., Ltd., MedImmune, Genentech, Merck, Pfizer, Takeda, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Inc., Camurus, Pfizer, Radiomedix, Inc. Orano Med, Clarity Pharmaceuticals, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis, Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison, Novatek Pharmaceuticals Ltd., Phanes Therapeutics, Inc., FUJIFILM Pharmaceuticals U.S.A., Inc., Jazz Pharmaceuticals, 23andMe, Celgene, Crinetics Pharmaceuticals, POINT Biopharma, and others are evaluating novel Neuroendocrine Tumors drugs to improve the treatment scenario.

Get a more detailed analysis at: 
https://lnkd.in/dbGeieBJ

#lifesciences #marketresearch #marketanalysis #healthcare #markettrends #health #medical #marketforecast #markettrends #consulting #healthcareconsulting #marketoutlook 

We are excited to share the news that RadioMedix together with business partner, Orano Med, completed patient enrolment in Phase II trial of targeted alpha-emitter therapy using AlphaMedix™ in Neuroendocrine Cancers. This trial is being conducted to evaluate the safety and effectiveness of AlphaMedix™ in peptide receptor radionuclide therapy (PRRT) of naive patients with somatostatin receptor-expressing neuroendocrine tumors (NET), regardless of the location of the primary tumor. Top-line data from the trial is expected in mid-2024.
Based on data already collected, the objective response rate (ORR) endpoint has already been achieved and is more than twice as high as the current standard of care.

For more information, please check the press release:
https://lnkd.in/gmqERfnp
#radiomedix, #Pb212, #oranomed, #neuroendocrinetumors, #targetedradiotherapy, #clinicalstudies

RadioMedix, Inc. announced the acquisition of it’s 225Ac-PSMA-I&T asset by Fusion Pharmaceuticals. 225Ac-PSMA-I&T is currently being evaluated under a phase 2 physician-sponsored investigational new drug (IND) under the acronym of TATCIST trial. RadioMedix will also provide manufacturing support to Fusion for the TATCIST trial and first pivotal clinical trial to evaluate the safety and efficacy of 225Ac-PSMA-I&T for metastatic castration-resistant prostate cancer (mCRPC). As currently designed, the trial is expected to evaluate approximately 100 patients with four treatment cycles per patient, occurring every eight weeks. Patients are initially dosed at 100 kBq/kg.#Ac225PSMAI&T #radiopharmaceuticals #TAT

COM:RADIOMEDIX

RadioMedix, Inc.

People Not Available